FDA says generics study is wrong

Share this article:

The FDA is questioning a study that found generics produced abroad included a notable degree of contamination. Bloomberg reports that the regulator is taking on a study presented at a February congressional hearing in which a Brigham & Women's Hospital researcher said he found contaminants among generics made abroad.

The FDA says it will be publishing its own study about generic heart medications, one that used a different testing approach. This approach, reports Bloomberg, did not find contaminants, and the regulator alleges that the Brigham & Women's Hospital researchers contaminated their own samples.

Concern about generics quality has not been hard to find over the last few weeks, particularly when it comes to disputes over drugs manufactured in India.

An FDA spokesperson tells Bloomberg that the regulator expects to publish its findings soon.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.